Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
We will perform double-blinded placebo-controlled randomized clinical trial which evaluates
the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for
allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat,
and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic
rhinitis.